The primary role of Cavid (Calcium Carbonate and Colecalciferol) is to address underlying nutrient deficits, supporting the body's mineral balance and contributing to the maintenance of skeletal structural integrity. It is commonly used as a routine daily supplement or may be part of symptomatic management for chronic conditions. The combination is generally indicated for the prevention and treatment of vitamin D and calcium deficiency, and as an adjunct to specific osteoporosis treatment in patients who are at risk of these deficiencies. The combination is applied across domains where additional symptomatic support is needed.

Key Therapeutic Focus

Cavid is commonly used across conditions presenting with systemic imbalance to correct chronic states of hypocalcemia (low blood calcium) and Vitamin D deficiency. Key indications include the long-term management of osteoporosis, the correction of nutrient shortfalls that may lead to osteomalacia or rickets, and support for patients with low dietary intake or limited sun exposure. This therapeutic area is also relevant for easing symptoms of increased neurological or muscular activity, such as cramps and spasms. Addressing these deficiencies offers the therapeutic benefit that may assist with managing or reducing the risk of bone conditions and supports general well-being during symptomatic phases.

Quick Fact: Relief for Musculoskeletal Symptoms
Cavid is commonly used to help with symptomatic manifestations of mineral imbalance and is applied in addressing muscle cramps and spasms that interfere with daily comfort.

Who Can and Cannot Use Cavid?

Cavid, a combination of Calcium Carbonate and Colecalciferol (Vitamin D3), is generally intended for use by adults and the elderly for documented nutritional deficiencies. Its use is strictly defined by regulatory eligibility rules to prevent complications arising from excessive mineral levels.

---

Populations Who Must NOT Use Cavid (Contraindications)

The medicine is contraindicated and must not be used by patients with pre-existing conditions that affect calcium balance, as stated in official labeling:

• Hypercalcemia, Hypercalciuria, or Hypervitaminosis D (existing high levels of calcium or Vitamin D in the body).
• Severe Renal Impairment (severe kidney failure) or Nephrolithiasis (kidney stones).
• Hypersensitivity (allergy) to any of the active ingredients or excipients.

---

Restricted and Conditional Use

Use is permitted in the following groups only under conditional supervision, as detailed in regulatory warnings:

• Mild to Moderate Renal Impairment: Requires careful monitoring of calcium and phosphate levels.
• Sarcoidosis or Immobilized Patients: Requires close supervision due to an increased risk of hypercalcemia.
• Pregnancy and Lactation: Use is permitted, but daily dosage must not exceed officially established safety limits.
• Pediatric Population: Specific high-dose formulations are not recommended for children and adolescents.

Interactions with other medicines and products

Co-administration of Cavid, a fixed-dose combination of Calcium Carbonate and Colecalciferol (Vitamin D3), with certain other medicinal products can result in clinically significant interaction patterns, as documented in official regulatory labeling.

Pharmacodynamic and Additive Risk Interactions

Regulatory information documents a risk of hypercalcaemia when Cavid is co-administered with other high-dose sources of Vitamin D (a contraindicated combination) or thiazide diuretics, as these reduce the urinary excretion of calcium. Hypercalcaemia can, in turn, intensify the toxicity of cardiac glycosides (e.g., Digoxin), which necessitates careful monitoring in affected patients.

Interactions Affecting Absorption

The calcium carbonate component can reduce the absorption and subsequent plasma concentration of several co-administered medicinal products, including quinolone and tetracycline antibiotics, bisphosphonates, and Levothyroxine (thyroid hormones). The reduction in absorption for these substances requires mandatory separation of administration, such as administering Levothyroxine at least four hours apart from Cavid. The efficacy of the Colecalciferol component may also be reduced by drugs like Rifampicin or Phenytoin, as well as by substances such as Cholestyramine and mineral oil.

Drug-Food Constraints

Official labeling documents that oxalic acid (found in spinach and rhubarb) and phytic acid (found in whole cereals) can inhibit calcium absorption. Cavid should not be taken within two hours of consuming foods high in these acids.

Cavid is a novel pharmacologic agent that mediates its effects through the modulation of specific, dysregulated biological pathways, resulting in modified physiological responses. Its mechanism of action is characterized by targeted interaction across key functional domains.

---

Modulation of Receptor-Mediated Signaling

Cavid acts within domains involving receptor-mediated signaling by selectively binding to specific membrane receptors, functioning as a pathway antagonist. This binding event initiates or suppresses subsequent signaling sequences, leading to modified early molecular steps. This action influences the regulation of processes driven by distinct signaling patterns within the cell.

---

Regulation of Dysregulated Signaling Cascades

The drug engages mechanisms that regulate overactive or dysregulated intracellular processes by modifying key enzymatic steps in downstream signaling cascades. This activity restricts the magnitude of excessive mediator release and modulates overactive physiological responses within targeted systems where specific transmitters or mediators dominate.

---

Targeted Pathway Adjustment

Cavid is utilized in biological systems where targeted pathway adjustment is required, specifically influencing pathways that exhibit heightened activity. By modifying the activity of these pathways, the drug induces physiological adjustments within targeted pathways.

How to Use Cavid

Cavid, a fixed-dose combination of Calcium Carbonate and Colecalciferol (Vitamin D3), is strictly for oral administration. The specific instructions for use depend on the dosage form provided.

Administration and Dosage Regimens

The standard adult daily dose generally falls within a range that delivers 1,000 mg to 1,200 mg of elemental calcium combined with 800 IU to 880 IU of Vitamin D3. This is often achieved through a once daily or twice daily schedule, with the two-tablet regimen frequently used to space the daily calcium intake for enhanced absorption.

Dosage Form Instructions	Procedural Requirement
Chewable Tablets	Must be thoroughly chewed or sucked before swallowing.
Effervescent Tablets	Must be fully dissolved in a glass of water and consumed immediately.

Contextual Use and Timing

While Cavid can often be taken without strict regard to mealtimes, certain film-coated tablets are recommended for intake within one and a half hours of a meal. It is procedurally necessary to separate Cavid administration from the consumption of foods high in oxalic or phytic acid by at least two hours, as these substances can inhibit calcium absorption. Additionally, the medicine must be separated by a minimum of two to six hours from co-administered drugs like tetracycline antibiotics and bisphosphonates to avoid interference with absorption.

Population-Specific Rules

Use is considered long-term for correcting chronic deficiencies. Specific limitations apply to certain groups: the daily intake in pregnant individuals from all sources should not exceed 1,500 mg of calcium and 600 IU of Vitamin D3. The product must not be used in patients with severe renal impairment.

Research Evidence / Overview of Studies for Cavid

Evidence for Correcting Calcium and Vitamin D Deficiency

The primary body of research for this combination involves studies that have explored how supplementation was evaluated in the context of low levels of calcium and Vitamin D in the body. These studies typically include short-term to intermediate-term intervention trials and observational research.

What Researchers Studied and Reported Researchers designed trials to assess the ability of the combination to modify serum biomarkers—measurable substances in the blood that indicate nutrient status. Studies monitored in these trials reported that the supplement findings described changes in the measured target ranges for these key nutrient biomarkers, particularly in individuals who began the study with low baseline levels. Research describes the main pattern observed as an evaluation of the nutrient deficits themselves.

Studies on Bone Health and Fracture Risk in Osteoporosis

The combination of calcium and Vitamin D has been extensively studied for its evaluation as an addition to specific prescription treatments for osteoporosis, such as bisphosphonates. This area of evidence is primarily supported by large-scale Randomized Controlled Trials (RCTs) and subsequent systematic reviews.

What Researchers Studied and Reported Studies evaluated two main types of outcomes in populations, including postmenopausal women and older adults: surrogate measures like Bone Mineral Density (BMD), and hard clinical outcomes like the incidence of new fractures (e.g., hip or total non-vertebral fractures). The findings reported by comprehensive meta-analyses explored whether the combination's use alongside primary anti-osteoporosis therapy coincided with patterns related to fracture rates in specific high-risk groups, such as frail or institutionalized older adults.

Research on Fracture Risk in General Supplementation

The research has also explored how calcium and Vitamin D supplementation was evaluated in older adults in the general community. This evidence is derived from long-term, large-scale RCTs focusing on outcomes related to bone structure maintenance and measured fracture events.

What Researchers Studied and Reported In this research scenario, studies monitored fracture patterns and assessed changes in BMD over several years in community-dwelling older adults. The findings regarding fracture patterns varied significantly across the major RCTs. While some pooled analyses reported findings related to fracture outcomes, this pattern was not consistently described in study participants who were generally healthy or already had adequate nutrient intake at baseline.

Consistency and Limitations of the Evidence

The most notable research limitation is the variability across studies when analyzing fracture outcomes in general populations. Additionally, while certain subgroups, such as institutionalized older adults, have been the focus of targeted trials, data for certain groups—including children or pregnant populations—remain insufficient, meaning that results apply only to the specific populations studied in the official research. Finally, comparative evidence is lacking in many areas, meaning research provides insight into short-term changes, but research cannot establish certainty on whether an individual will respond similarly to group patterns.

Key Studies & References

1. Vitamin D, Calcium, or Combined Supplementation for the Primary Prevention of Fractures (U.S. Preventive Services Task Force - USPSTF)
2. Vitamin D and Calcium in Osteoporosis, and the Role of Bone Turnover Markers: A Narrative Review of Recent Data from RCTs

Common questions about Cavid (FAQ)

---

Q: Is Cavid the same type of medicine as [similar drug name]?

A: Cavid is officially defined as a fixed-dose combination product, containing two active ingredients: calcium carbonate and colecalciferol (Vitamin D3). It is classified as a Mineral and Vitamin Supplement. Fixed-dose combinations are officially recognized as products where all active ingredients contribute to the intended purpose.

Q: Is feeling tired a common side effect of Cavid?

A: Feeling tired or experiencing fatigue is not listed as a common or rare side effect in the official product information. However, unusual weakness is an officially recognized symptom associated with high calcium levels in the blood (Hypercalcemia), which itself is listed as an uncommon adverse reaction. If weakness occurs, it is an important change to note.

Q: Is it possible to take Cavid with over-the-counter pain relievers?

A: Official guidance on timing separation is focused on certain prescription drugs, such as tetracyclines or levothyroxine, to prevent absorption interference. If taking other medicines, separating the administration of Cavid is a documented approach to prevent absorption interference.

Q: Can Cavid affect mood or sleep?

A: Official regulatory documents do not list changes in mood or sleep as common or rare side effects. However, in rare instances, a serious adverse reaction involving high calcium levels (Hypercalcemia) may lead to mental confusion. Any significant changes in mood or signs of confusion are important to monitor and discuss with a healthcare provider.

Q: Is Cavid known to cause stomach upset?

A: Yes, official documentation lists specific gastrointestinal problems as rare side effects. These include constipation, flatulence (gas), nausea, abdominal pain, and diarrhea. If these effects occur, they are important to note, as the product label classifies them as rare.

Q: What is the general difference between Cavid and other drugs in its class?

A: Cavid is a supplement belonging to the ant-hypocalcemic class, and it is a fixed-dose combination. This means it is formulated to deliver two essential components—calcium and Vitamin D—together in one pill. Other products in this class may contain only one of these components, making Cavid distinct by its dual-ingredient structure.

Q: Are people with kidney problems allowed to take Cavid?

A: Use of Cavid is strictly defined by existing conditions. Official documents state that Cavid must not be used by patients with severe renal impairment (severe kidney failure) or a history of kidney stones. Use in patients with mild to moderate kidney impairment is permitted but requires close supervision and monitoring of mineral levels.

Q: How quickly can one expect Cavid to start working?

A: As Cavid is a supplement for deficiency correction, its full therapeutic effect on skeletal health develops over time, often months. While studies show it begins to modulate nutrient biomarkers in the blood relatively quickly, its primary purpose is long-term maintenance. Significant changes are observed over intermediate to long-term periods of consistent use.

Q: Does Cavid need to be taken long-term?

A: Official regulatory information describes Cavid as a long-term treatment for the correction of chronic deficiencies or as supplementation alongside osteoporosis therapy. The safety information regarding the risks of high mineral levels (Hypercalcaemia) is specifically associated with continuous long-term treatment at higher dosages.

Q: Are there different strengths of Cavid available?

A: Regulatory documents describe a standard adult daily dose, and different fixed-dose preparations of the two components may be available. The dose is typically formulated to deliver 1,000 mg to 1,200 mg of elemental calcium and 800 IU to 880 IU of Vitamin D3.

Q: Has Cavid been studied in children?

A: Official warnings state that specific high-dose formulations are not recommended for children and adolescents. While some research may exist, the overall evidence summary notes that data for the pediatric population remain insufficient. Therefore, the official findings and recommendations apply primarily to the specific adult populations studied.

Q: Do I need to take Cavid at a specific time of day?

A: The product information states that certain types of Cavid tablets are recommended for intake within one and a half hours of a meal. There is no requirement in the official documents to take the medicine at a specific time of day (e.g., morning or evening), only a recommendation to coordinate it with food for some formulations.

Q: Is it normal to feel a change in appetite while on Cavid?

A: A change in appetite (such as loss of appetite, or anorexia) is not listed as a common or rare side effect. However, a loss of appetite is an official symptom associated with the uncommon adverse reaction of high calcium levels (Hypercalcaemia). Any significant change in appetite is an important observation to discuss with a healthcare provider.

Q: Are there any specific organs Cavid can affect long-term?

A: The primary long-term safety concern documented is the accumulation of minerals, which can specifically affect the kidneys. Official documents state that severe renal impairment is a contraindication. Extreme accumulation, often associated with overdose, can lead to systemic conditions like Milk-alkali syndrome that affect various organs.

Q: Why do people sometimes stop taking Cavid?

A: Official regulatory documents specify that treatment must be reduced or interrupted if a patient develops specific adverse events, such as high calcium levels in the blood (Hypercalcaemia) or high calcium levels in the urine (Hypercalciuria). These mineral imbalances are the most common documented reasons that may necessitate temporary or permanent cessation.

Q: What are the key findings from the main clinical trials for Cavid?

A: The key findings summarized in the research evidence focus on two areas: 1) The ability to correct serum nutrient biomarkers in individuals with low baseline levels, and 2) Studies on bone health, which explored patterns related to fracture rates and Bone Mineral Density (BMD) when used alongside primary osteoporosis therapies.

Q: Does Cavid affect driving or operating machinery?

A: Official product information for Cavid and similar products generally states that the medicine is expected to have no or negligible effects on the ability to drive and use machines. The known side effect profile does not typically include nervous system effects that would impair these activities.

Q: Can Cavid be crushed or split?

A: The administration section provides specific directions for chewable tablets (must be chewed or sucked) and effervescent tablets (must be dissolved). For other forms, such as film-coated tablets, the lack of specific instructions to cut or crush implies they should be swallowed whole. Always follow the specific instructions for the product form you have.

Q: Can Cavid interfere with laboratory tests?

A: Yes, Cavid is known to affect certain laboratory biomarkers. Because the product is intended to increase calcium and Vitamin D levels, it can directly influence key measurements like serum and urinary calcium and phosphate. Regulatory documents emphasize that monitoring these levels is necessary, particularly during long-term treatment.

Q: Do studies suggest Cavid is effective for all types of the treated condition?

A: Official research findings have shown variability. The research evidence states that results regarding fracture patterns, especially in the general community of older adults, have varied significantly across major studies. The pattern of effect was not consistently described in all study participants, particularly those who already had adequate nutrient intake at baseline.

Q: Is Cavid suitable for individuals with diabetes?

A: According to official regulatory documents, diabetes mellitus is not listed as a contraindication or as a special warning requiring caution. The primary safety concerns revolve around mineral imbalances and kidney function.

Official Storage and Disposal Conditions for Cavid

Regulatory documents specify strict conditions for storing Cavid (Calcium Carbonate and Colecalciferol) to maintain the quality and stability of the active ingredients, particularly the Vitamin D3 component.

Requirement	Official Instruction
Temperature	Store at Controlled Room Temperature, typically below 25 C or 30 C. Do not freeze.
Protection	Protect from light and moisture. Keep the medicine in its original container and tightly closed where applicable.
Child Safety	Keep out of the sight and reach of children at all times.
Disposal	Do not dispose of via wastewater or household trash. Dispose of unused or expired product through local pharmaceutical waste schemes or a pharmacist.